Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Necrosis01:16

Necrosis

4.7K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.7K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.0K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.0K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

18
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

13
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
13
The Early Endosome: Endocytosis of Transferrin01:28

The Early Endosome: Endocytosis of Transferrin

3.4K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
3.4K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

759
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
759

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same author

Journal update monthly top five.

Emergency medicine journal : EMJ·2026
Same author

Alcohol abstinence and recompensation - time to understand the 'how?'

Journal of hepatology·2026
Same author

Noninvasive Prediction of Decompensation in Compensated Advanced Chronic Liver Disease and a Liver Stiffness From 15 to 25 kPa.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-up.

BMJ open·2026
Same author

Outcomes of first and further decompensation events in advanced chronic liver disease: a multi-centre competing risks analysis.

Hepatology international·2026
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Aug 1, 2025

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

4.7K

La hemocromatosis

Paul C Adams1, Gary Jeffrey2, John Ryan3

  • 1Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.

Lancet (London, England)
|April 30, 2023
PubMed
Resumen
Este resumen es generado por máquina.

La hemocromatosis, un trastorno genético común, a menudo es mal diagnosticada. Las pruebas genéticas tempranas y el tratamiento de flebotomía pueden prevenir complicaciones graves como enfermedad hepática y muerte.

Más Videos Relacionados

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.0K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Videos de Experimentos Relacionados

Last Updated: Aug 1, 2025

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

4.7K
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.0K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Área de la Ciencia:

  • La genética médica
  • Hepatología
  • Médico interno

Sus antecedentes:

  • La hemocromatosis es un trastorno genético frecuente, especialmente en personas de ascendencia del norte de Europa.
  • La condición es frecuentemente mal diagnosticada, lo que lleva a un sobrediagnóstico en aquellos sin sobrecarga de hierro y a un subdiagnóstico en los individuos afectados.
  • Si no se trata, pueden surgir complicaciones graves, como cirrosis hepática, cáncer de hígado y mortalidad.

Objetivo del estudio:

  • Para proporcionar una visión general actualizada de la hemocromatosis.
  • Para discutir la fisiopatología, la genética y la presentación clínica de la enfermedad.
  • Revisar las estrategias diagnósticas y terapéuticas, centrándose en la flebotomía.

Principales métodos:

  • Revisión de la literatura actual y de las directrices clínicas.
  • Análisis de las pruebas genéticas y criterios de diagnóstico.
  • Evaluación de los resultados terapéuticos y las direcciones futuras de la investigación.

Principales resultados:

  • Las pruebas genéticas permiten el diagnóstico precoz de la hemocromatosis.
  • La flebotomía periódica es un tratamiento eficaz para controlar la sobrecarga de hierro.
  • La intervención oportuna reduce significativamente el riesgo de complicaciones graves.

Conclusiones:

  • El diagnóstico preciso a través de pruebas genéticas es crucial para una gestión eficaz.
  • La flebotomía sigue siendo la piedra angular del tratamiento de la hemocromatosis.
  • Se necesita una investigación continua para refinar el entendimiento y mejorar los resultados de los pacientes.